Biologics and Biosimilars as Treatment Options for Psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.
| Hoofdauteur: | |
|---|---|
| Andere auteurs: | |
| Formaat: | Thesis |
| Taal: | en_US |
| Gepubliceerd in: |
Brac University
2023
|
| Onderwerpen: | |
| Online toegang: | http://hdl.handle.net/10361/17712 |
| id |
10361-17712 |
|---|---|
| record_format |
dspace |
| spelling |
10361-177122023-01-10T21:05:24Z Biologics and Biosimilars as Treatment Options for Psoriasis Moya, Amena Khatun Kabir, Dr. Eva Rahman Department of Pharmacy, Brac University Biologics Biosimilars Psoriasis Inflammation Treatment Skin--Diseases Psoriasis. This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. Cataloged from PDF version of thesis. Includes bibliographical references (pages 34-43). Psoriasis is a common chronic skin disease stemming from a systemic inflammatory disorder. It affects more than 7.5 million people in the United States and an estimated 125 million people worldwide. It is an immune-mediated disease that causes indurated, erythematous, scaly, pruritic, and often painful skin plaques. Current treatments for psoriasis include topical agents, standard systemic phototherapy, as well as phototherapy combined with psoralen and ultraviolet A radiation. However, these treatments were not always effective which led to the discovery of biologics and biosimilars. Biologics such as T-Cell Targeted biologics (Alefacept, Efalizumab) tumor necrosis factor inhibitors (Infliximab, Adalimumab, Etanercept), IL17 inhibitors (Secukinumab, Ixekizumab) and IL 12/IL 23 inhibitors (Ustekinumab) have been successfully used to treat psoriasis. This was later followed by the introduction of safe and effective biosimilars that increased access to these highly effective medications. Amena Khatun Moya B. Pharmacy 2023-01-10T09:21:52Z 2023-01-10T09:21:52Z 2022 2022-02 Thesis ID: 18146035 http://hdl.handle.net/10361/17712 en_US Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 43 Pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
en_US |
| topic |
Biologics Biosimilars Psoriasis Inflammation Treatment Skin--Diseases Psoriasis. |
| spellingShingle |
Biologics Biosimilars Psoriasis Inflammation Treatment Skin--Diseases Psoriasis. Moya, Amena Khatun Biologics and Biosimilars as Treatment Options for Psoriasis |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. |
| author2 |
Kabir, Dr. Eva Rahman |
| author_facet |
Kabir, Dr. Eva Rahman Moya, Amena Khatun |
| format |
Thesis |
| author |
Moya, Amena Khatun |
| author_sort |
Moya, Amena Khatun |
| title |
Biologics and Biosimilars as Treatment Options for Psoriasis |
| title_short |
Biologics and Biosimilars as Treatment Options for Psoriasis |
| title_full |
Biologics and Biosimilars as Treatment Options for Psoriasis |
| title_fullStr |
Biologics and Biosimilars as Treatment Options for Psoriasis |
| title_full_unstemmed |
Biologics and Biosimilars as Treatment Options for Psoriasis |
| title_sort |
biologics and biosimilars as treatment options for psoriasis |
| publisher |
Brac University |
| publishDate |
2023 |
| url |
http://hdl.handle.net/10361/17712 |
| work_keys_str_mv |
AT moyaamenakhatun biologicsandbiosimilarsastreatmentoptionsforpsoriasis |
| _version_ |
1814306932644642816 |